Palliative care - nausea and vomiting
Exam Tips
- In palliative OSCEs, always state that nausea/vomiting is often multifactorial and that management should target the dominant receptor pathway while checking for reversible causes.
- Pattern recognition is high yield: large-volume intermittent vomits with relief suggest gastric stasis; faeculent vomit plus colic suggests distal obstruction; morning headache/drowsiness suggests raised intracranial pressure.
- Mention treatment burden and goals of care explicitly: decide whether to pursue investigations/interventions based on prognosis, patient preference, and likely benefit.
- Safety marks: avoid metoclopramide in complete obstruction, monitor QT risk with haloperidol/ondansetron, and review steroid adverse effects.
- Differentiate vomiting from regurgitation/reflux, as this changes mechanism-based antiemetic choice.
Definition
In palliative care, nausea is a distressing subjective urge to vomit and vomiting is the coordinated expulsion of gastric contents via brainstem-mediated reflex pathways. They are common, often multifactorial symptoms in advanced illness, and may arise from chemical, gastrointestinal, vestibular, or intracranial triggers, with major effects on hydration, nutrition, comfort, and quality of life.
Pathophysiology
Emesis is coordinated by a medullary vomiting centre integrating inputs from the chemoreceptor trigger zone (area postrema, relatively outside the blood-brain barrier), vagal/splanchnic afferents from the gut, vestibular pathways, and higher cortical centres. In palliative patients, receptor stimulation is frequently mixed: dopamine/serotonin-mediated chemical triggers (for example opioids, uraemia, hypercalcaemia), mechanoreceptor stretch from constipation or obstruction, delayed gastric emptying, and intracranial pressure effects can all coexist. The final common pathway produces autonomic prodrome (pallor, sweating, salivation), retching (against closed glottis), then forceful emesis; regurgitation/reflux are passive and should be distinguished clinically. See Figure: emetic pathways (CTZ-vomiting centre-vagal/vestibular/cortical inputs) in standard palliative medicine texts (for example Regnard/Hardy chapters on nausea-vomiting).
Risk Factors
- Advanced cancer (high symptom burden, especially near end of life)
- Recent opioid initiation or dose escalation
- Other emetogenic drugs (cytotoxics, antibiotics, NSAIDs, iron, digoxin, anticholinergics, tricyclics)
- Metabolic disturbance (renal/hepatic failure, hypercalcaemia)
- Constipation or bowel obstruction
- Gastric stasis/gastroparesis, ascites, hepatomegaly
- Intracranial disease (tumour, oedema, haemorrhage, meningeal involvement)
- Vestibular sensitivity/motion
- Radiotherapy (especially abdominal/CNS fields)
- Anxiety and conditioned nausea responses
Clinical Features
Symptoms
- Persistent or intermittent nausea, sometimes in waves
- Vomiting pattern clues: large-volume infrequent vomits with transient relief (gastric stasis), forceful vomiting with dehydration (gastric outflow obstruction), low-volume vomiting with external gastric compression
- Post-prandial vomiting of recently swallowed contents with dysphagia sensation (oesophageal obstruction)
- Colicky abdominal pain, bloating, worsening nausea, possible faeculent vomit (bowel obstruction)
- Morning-predominant nausea/vomiting, headache, drowsiness, movement-triggered worsening (raised intracranial pressure/vestibular component)
- Associated reflux, early satiety, epigastric fullness, hiccups, constipation, reduced oral intake
Signs
- Dehydration (dry mucosa, tachycardia, postural hypotension)
- Cachexia or poor nutritional state
- Abdominal distension or altered bowel sounds; tenderness if obstruction/irritation
- Succussion splash suggesting gastric stasis
- Neurological signs of raised intracranial pressure (papilloedema may be present)
- Oral pathology (candidiasis, ulceration, tumour, poor dentition)
- Confusion or drowsiness from metabolic/toxic causes
Investigations
Management
Lifestyle Modifications
- Agree goals of care first (reversible-cause treatment vs symptom-focused palliation) with patient/family and MDT
- Use non-drug measures: small frequent meals, avoid strong smells/fatty foods, upright posture after intake, cool room and airflow
- Regular mouth care and hydration support (oral/sips/assisted fluids as appropriate)
- Treat reversible contributors early (constipation, reflux, infection, medication triggers)
- Provide psychological support/distraction for anxiety-conditioned nausea
Pharmacological Treatment
Dopamine antagonist / prokinetic (gastric stasis-dominant pattern)
- Metoclopramide 10 mg PO or SC up to three times daily (maximum 30 mg/24 h)
Avoid in complete bowel obstruction, Parkinson disease, and with levodopa; risk of extrapyramidal effects/tardive dyskinesia (higher risk in younger adults and prolonged use).
Broad dopamine blockade for chemical nausea
- Haloperidol 0.5-1.5 mg PO or SC at night; may titrate in divided doses (commonly up to 5 mg/24 h in palliative practice)
Check QT-risk factors and interacting QT-prolonging medicines; use lower doses in frailty/hepatic impairment and monitor for akathisia/parkinsonism.
Antihistamine/anticholinergic (vestibular or raised intracranial pressure-related nausea)
- Cyclizine 50 mg PO/IM/IV/SC up to three times daily (maximum 150 mg/24 h)
Can worsen anticholinergic burden (confusion, urinary retention, dry mouth); caution in severe heart failure and angle-closure glaucoma risk.
5-HT3 antagonist (drug/radiotherapy-related nausea, bowel obstruction adjunct)
- Ondansetron 4-8 mg PO/IV/SC every 8-12 hours (typical maximum 16 mg/day in many palliative regimens)
Commonly causes constipation and headache; monitor QT interval risk and correct electrolytes.
Corticosteroid (intracranial pressure, bowel obstruction, capsular stretch/inflammation)
- Dexamethasone 4-8 mg PO/SC each morning; may increase to 8-16 mg/day for selected severe indications
Use lowest effective dose and review frequently; adverse effects include hyperglycaemia, proximal myopathy, mood change/psychosis, infection risk, and GI irritation.
Broad-spectrum antiemetic when first-line fails or cause is mixed/uncertain
- Levomepromazine 6.25 mg PO or SC at night; titrate cautiously (for example 6.25-25 mg/24 h via CSCI)
Highly sedating and can cause postural hypotension and anticholinergic effects; start low in older/frail patients.
Malignant bowel obstruction secretion-reduction strategy
- Hyoscine butylbromide 20 mg SC every 4-6 hours or 60-120 mg/24 h by continuous SC infusion
- Octreotide 100-300 micrograms/24 h by continuous SC infusion (or 50-100 micrograms SC 2-3 times daily)
Useful when colic/secretions drive vomiting; monitor anticholinergic adverse effects (hyoscine) and glucose/gallbladder effects with longer octreotide use.
Surgical / Interventional
- Nasogastric decompression for acute symptomatic relief in obstruction when appropriate
- Endoscopic stenting for selected upper GI or colonic malignant obstruction
- Venting gastrostomy for refractory recurrent vomiting in inoperable obstruction
- Palliative surgery (for example bypass/diversion) only in carefully selected patients with acceptable performance status and goals
Complications
- Dehydration and electrolyte disturbance, including metabolic alkalosis after severe/prolonged vomiting
- Reduced nutritional intake and weight loss
- Aspiration pneumonia
- Oesophageal mucosal injury or tear
- Functional decline and reduced ability for self-care
- Major deterioration in quality of life
Prognosis
Nausea and vomiting are very common in advanced cancer (roughly half to two-thirds of patients) and typically become more prevalent as death approaches. Prognosis depends on whether a reversible driver is found and on overall disease trajectory; even when cure is not possible, mechanism-led antiemetic therapy and supportive care usually improve comfort.
Sources & References
🏥BMJ Best Practice(1)
💊BNF Drug References(16)
- Aprepitant[management.pharmacological]
- Chlorpromazine hydrochloride[management.pharmacological]
- Cinnarizine[management.pharmacological]
- Cyclizine[management.pharmacological]
- Domperidone[management.pharmacological]
- Doxylamine with pyridoxine[management.pharmacological]
- Droperidol[management.pharmacological]
- Fosaprepitant[management.pharmacological]
- Granisetron[management.pharmacological]
- Haloperidol[management.pharmacological]
- Levomepromazine[management.pharmacological]
- Metoclopramide hydrochloride[management.pharmacological]
- Ondansetron[management.pharmacological]
- Prochlorperazine[management.pharmacological]
- Promethazine teoclate[management.pharmacological]
- Trifluoperazine[management.pharmacological]
✅NICE Guidelines(1)
- Palliative care - nausea and vomiting[overview]
📖Textbook References(20)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1837, 1838)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 253, 254)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 327)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 377)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1098)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1098)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1072, 1073)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 643)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1019)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1570, 1571)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1278)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 273)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 383)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 419, 420)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 308)[context]
- Emergencies in - Obstetrics and Gynaecology, Second Edition (Stergios K. Doumouchtsis, S. Arulkumaran) (Z-Library).pdf(pp. 173, 174)[context]
- Emergencies in - Obstetrics and Gynaecology, Second Edition (Stergios K. Doumouchtsis, S. Arulkumaran) (Z-Library).pdf(pp. 36, 37)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 257)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 621, 622)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 256)[context]